Tag: Biomarkers

PCa17: What to expect in future prostate cancer management

The number of promising biomarkers at different molecular levels are increasing, accompanied by numerous testing in the market, but cancer experts say independent and prospective validation is crucial to help the medical community eventually provide optimal care to cancer...

EMUC17: Using biomarkers in decision-making for RCC treatment

Renal cell carcinomas are among the most lethal in urological malignancies prompting doctors to search for tools such as biomarkers and other molecular techniques to distinguish aggressive diseases. With new research outcomes, physicians are hopeful that diagnosis and therapy...

“Prioritise prospective studies and real-world data”

The EAU Research Foundation is uniquely placed to conduct and coordinate important prospective trials in the coming years, its new chairman has told European Urology Today. Prof. Anders Bjartell (Malmö, SE) took over chairmanship of the EAU Research Foundation...

Understanding the role of biomarkers in PCa treatment

With the current emphasis on providing personalised treatment to prostate cancer patients, expectations on the role of biomarkers may have been too high and experts say delivering optimal management requires understanding the usefulness of biomarkers within the context of...

Where do we stand with predictive biomarkers in mCRPC?

Treatment options for men with metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, cabazitaxel and radium-2231-6. With evidence that both abiraterone acetate and enzalutamide are effective agents when administered...